Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Pediatric Morphea: Early Recognition, Treatment, and 3D Monitoring of Craniofacial Disease
Description
The talk focused on pediatric morphea, emphasizing early recognition, accurate assessment of activity, and timely treatment to prevent irreversible damage. The speaker distinguished morphea from systemic sclerosis, noting it does not involve internal organs and encouraging use of the term morphea to reduce confusion. Linear morphea in children was highlighted as the most common subtype and the most concerning, especially when crossing joints, because it can cause limb undergrowth, contractures, functional disability, and long diagnostic delays. The natural history of disease activity was reviewed, with a warning that linear morphea may lack obvious erythema, so relying on redness alone can lead to undertreatment. Consensus treatment plans were summarized: severe disease is generally treated with methotrexate plus pulsed IV steroids or a prednisone taper, methotrexate alone may be used in less extensive cases, mycophenolate is second line, and topical therapy alone is insufficient. The speaker also discussed clinical pitfalls such as morphea masquerading as scarring alopecia and being triggered by trauma or surgery. For craniofacial morphea, the presentation can be subtle and difficult to monitor with routine exam or 2D photos, so the team used 3D stereophotogrammetry with facial heat maps to detect both obvious and occult progression over time. This method was shown to correlate with clinical assessment and sometimes reveal progression not seen on exam. Once disease was controlled, patients could undergo autologous fat transfer for cosmetic and functional restoration, with some remarkable improvements in facial symmetry.
View moreConclusions
- Pediatric morphea, especially linear morphea, is often the most clinically important subtype because it commonly affects children and can cause undergrowth, contractures, and long-term functional disability.
- Linear morphea can look deceptively inactive because erythema may be absent, so relying on redness alone risks underdiagnosis and undertreatment.
- Early recognition and aggressive treatment are necessary because damage such as atrophy and limb-length discrepancy can become irreversible once established.
- Consensus treatment plans support methotrexate-based systemic therapy for severe pediatric morphea, often combined with corticosteroids, while topical therapy alone is inadequate for significant disease.
- In craniofacial morphea, standard clinical follow-up with history, exam, and 2D photos may miss subtle progression, especially in children whose growth complicates assessment.
- 3D stereophotogrammetry appears to improve monitoring of craniofacial morphea by corroborating clinical impressions and detecting occult progression not obvious on exam.
- Once craniofacial morphea is inactive or in remission, autologous fat transfer can meaningfully improve facial symmetry and cosmetic outcomes.
- Overall, the presentation argues for vigilant whole-body examination, early systemic treatment, and use of advanced 3D imaging to better guide management and prevent permanent morbidity in pediatric morphea.
- Christen-Zaech S, Hakim MD, Afsar FS, Paller AS. Pediatric morphea (localized scleroderma): Review of 136 patients. Journal of the American Academy of Dermatology. September 2008.#10.1016/j.jaad.2008.05.005
- Development of Consensus Treatment Plans for Juvenile Localized Scleroderma. Arthritis Care & Research. 2012.
- Shaw KS, Nguyen TT, Rajah A, et al. Use of 3-Dimensional Stereophotogrammetry to Detect Disease Progression in Craniofacial Morphea. October 11, 2023.#10.1001/jamadermatol.2023.3649